ResearcherHeidelberg UniversityNo recent work listed
Nicolas Hohmann
Matched on ORCID iD 0000-0001-8036-8806; OpenAlex author ID A5090671577. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 38
2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 2 papers
Papers 7
- Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. Co-author DOI 10.1038/s43018-023-00628-6↗
- Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients w… Co-author DOI 10.1111/cts.13661↗
- Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects. Co-author DOI 10.1136/jitc-2021-002505↗
- Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-21-1020↗
- A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients w… First author DOI 10.1080/2162402x.2017.1303584↗
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… First author DOI 10.1080/2162402x.2014.1001217↗
- Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients… Co-author DOI 10.1186/1471-2407-12-361↗
Closest collaborators
The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christoph Springfeld · 5 shared papers, 2015–2023 · strength 0.46
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Jacek Hajda · 2 shared papers, 2021–2023 · strength 0.23
- Paper Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemc… DOI 10.1111/cts.13661↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Markus Wolfgang Büchler · 3 shared papers, 2012–2023 · strength 0.22
- Paper Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC. DOI 10.1038/s43018-023-00628-6↗
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Niels Halama · 2 shared papers, 2021 · strength 0.21
- Paper Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and … DOI 10.1136/jitc-2021-002505↗
- Paper Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With M… DOI 10.1158/1078-0432.ccr-21-1020↗
- Karen Steindorf · 1 shared paper, 2023 · strength 0.14
- Martin Ronald Sprick · 1 shared paper, 2023 · strength 0.14
- Andreas Trumpp · 1 shared paper, 2023 · strength 0.14
- Azaz Ahmed · 1 shared paper, 2023 · strength 0.14
- Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.14
- Jens Thomas Siveke · 1 shared paper, 2023 · strength 0.14
- Albrecht Stenzinger · 1 shared paper, 2023 · strength 0.14
- Peter J. Bailey · 1 shared paper, 2023 · strength 0.13
- Shigenori Ei · 1 shared paper, 2023 · strength 0.13
- Jingyu An · 1 shared paper, 2023 · strength 0.13
- Franco Fortunato · 1 shared paper, 2023 · strength 0.13
- Thilo Hackert · 1 shared paper, 2023 · strength 0.13
- Simon T. Barry · 1 shared paper, 2023 · strength 0.13
- Xu Zhou · 1 shared paper, 2023 · strength 0.13
- Dirk Theile · 1 shared paper, 2023 · strength 0.13
- John P. Neoptolemos · 1 shared paper, 2023 · strength 0.13
- Oliver Strobel · 1 shared paper, 2023 · strength 0.13
- Ulrike Heger · 1 shared paper, 2023 · strength 0.13
- Friedrich Hubertus Schmitz-Winnenthal · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Philipp Beckhove · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
- Lars Grenacher · 3 shared papers, 2012–2018 · strength 0.12
- Paper A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T ce… DOI 10.1080/2162402x.2017.1303584↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Paper Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction… DOI 10.1186/1471-2407-12-361↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.